Calvo, Emiliano
Azaro, Analia
Rodon, Jordi
Dirix, Luc
Huizing, Manon
Senecal, Francis Mark
LoRusso, Patricia
Yee, Lorrin
Poggesi, Italo
de Jong, Jan
Triantos, Spyros
Park, Youn C.
Knoblauch, Roland E.
Parekh, Trilok V.
Demetri, George D.
von Mehren, Margaret
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 2 November 2017
Accepted: 20 November 2017
First Online: 27 November 2017
Compliance with ethical standards
:
: The following authors declare that they have no conflict of interest: Emiliano Calvo, Analia Azaro, Luc Dirix, Manon Huizing, Patricia LoRusso, Francis Mark Senecal, and Lorrin Yee.Jordi Rodon: Member of Advisory Boards of Orion, Peptomyc, Novartis, Lilly, and Servier.George D. Demetri: Research support from Bayer, Novartis, Pfizer, and Janssen Oncology; Consulting fees from Novartis, EMD-Serono, Sanofi Oncology, Janssen Oncology, PharmaMar, Daiichi-Sankyo, Adaptimmune, and Eisai; Patent licensed to Novartis from Dana-Farber Cancer Institute with royalty paid to Dana-Farber Cancer Institute; Blueprint Medicines Member, Board of Directors, Member, Scientific Advisory Board, consulting fees, and equity (minor stake, public).Margaret von Mehren: Member of Janssen Advisory Board, and Scientific Steering Committee for the study in this report.The following authors are Janssen/Johnson & Johnson employees: Italo Poggesi (and shareholder), Jan de Jong (and stock owner), Spyros Triantos (and shareholder), Youn C. Park, Roland E. Knoblauch (and stock owner), and Trilok V. Parekh (and shareholder).
: Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.